These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 17922273)

  • 1. Effect of medical castration on CYP3A4 enzyme activity using the erythromycin breath test.
    Hutson PR; Oettel K; Douglas J; Ritter M; Messing E; Staab MJ; Alberti D; Horvath D; Wilding G
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):373-7. PubMed ID: 17922273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide.
    Shim M; Bang WJ; Oh CY; Lee YS; Cho JS
    Investig Clin Urol; 2019 Jul; 60(4):244-250. PubMed ID: 31294133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
    Hall MC; Fritzsch RJ; Sagalowsky AI; Ahrens A; Petty B; Roehrborn CG
    Urology; 1999 May; 53(5):898-902; discussion 902-3. PubMed ID: 10223480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
    Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
    BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormonal therapy of prostate cancer.
    Debruyne F
    Semin Urol Oncol; 2002 Aug; 20(3 Suppl 1):4-9. PubMed ID: 12198632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
    Garnick MB; Mottet N
    BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of surgical and medical castration on serum testosterone level in prostate cancer patients.
    Novara G; Galfano A; Secco S; Ficarra V; Artibani W
    Urol Int; 2009; 82(3):249-55. PubMed ID: 19440008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS; Pacificar JS; Shapiro CE; Williams SG
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.
    Klotz L; Miller K; Crawford ED; Shore N; Tombal B; Karup C; Malmberg A; Persson BE
    Eur Urol; 2014 Dec; 66(6):1101-8. PubMed ID: 24440304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm.
    Oefelein MG; Cornum R
    J Urol; 2000 Sep; 164(3 Pt 1):726-9. PubMed ID: 10953134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
    Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
    Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Characteristics, effects, side effects of the LH-RH agonist].
    Miyanaga N; Akaza H
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():177-81. PubMed ID: 12599567
    [No Abstract]   [Full Text] [Related]  

  • 13. Goserelin versus leuprolide in the chemical castration of patients with prostate cancer.
    Dias Silva É; Ferreira U; Matheus W; Faria EF; Silva GD; Saito M; de Souza AA; Laranjo A; Clark O; Magna LA; Castilho LN; Reis LO
    Int Urol Nephrol; 2012 Aug; 44(4):1039-44. PubMed ID: 22315155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T; Nishizawa K; Mitsumori K
    Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between body mass index and serum testosterone concentration in patients receiving luteinizing hormone-releasing hormone agonist therapy for prostate cancer.
    van der Sluis TM; van Moorselaar RJ; Meuleman EJ; ter Haar RW; Bui HN; Heijboer AC; Vis AN
    Urology; 2013 May; 81(5):1005-9. PubMed ID: 23465153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer.
    Yri OE; Bjoro T; Fossa SD
    Eur Urol; 2006 Jan; 49(1):54-8; discussion 58. PubMed ID: 16314038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical Trial.
    Østergren PB; Kistorp C; Fode M; Henderson J; Bennedbæk FN; Faber J; Sønksen J
    J Urol; 2017 Jun; 197(6):1441-1447. PubMed ID: 27939836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy.
    Gulley JL; Figg WD; Steinberg SM; Carter J; Sartor O; Higano CS; Petrylak DP; Chatta G; Hussain MH; Dahut WL
    J Urol; 2005 May; 173(5):1567-71. PubMed ID: 15821487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry.
    van der Sluis TM; Bui HN; Meuleman EJ; Heijboer AC; Hartman JF; van Adrichem N; Boevé E; de Ronde W; van Moorselaar RJ; Vis AN
    J Urol; 2012 May; 187(5):1601-6. PubMed ID: 22425112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation Between Testosterone and PSA Kinetics in Metastatic Prostate Cancer Patients Treated With Diverse Chemical Castrations.
    Reis LO; Denardi F; Faria EF; Silva ED
    Am J Mens Health; 2015 Sep; 9(5):430-4. PubMed ID: 25294865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.